TherapeuticsMD, Inc.

For the period ended Dec 31, 2024. Filed Mar 27, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 27, 2025

TXMD$1.69-2.9%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(In thousands, except per share amounts)

	As of December 31,
	2024	2023
Assets:
Current assets:
Cash and cash equivalents	$5,059	$4,327
Royalty receivable, current portion	3,562	3,090
Prepaid and other current assets	3,638	4,035
Current assets of discontinued operations	—	344
Total current assets	12,259	11,796
License rights and other intangible assets, net	4,321	6,098
Right of use assets, net	6,102	6,873
Royalty receivable, long term	16,010	18,484
Other non-current assets	130	58
Total assets	$38,822	$43,309
Liabilities and stockholders’ equity:
Current liabilities:
Accounts payable	$258	$27
Accrued expenses and other current liabilities	2,127	3,133
Current liabilities of discontinued operations	2,781	3,694
Total current liabilities	5,166	6,854
Operating lease liabilities	5,542	6,532
Other non-current liabilities	744	636
Total liabilities	11,452	14,022
Commitments and contingencies (Note 7)
Stockholders’ equity:
Common stock, par value $0.001; 32,000 and 12,000 shares authorized, 11,532 and 11,532 issued and outstanding as of December 31, 2024 and December 31, 2023, respectively	11	11
Additional paid-in capital	979,181	978,917
Accumulated deficit	(951,822)	(949,641)
Total stockholders’ equity	27,370	29,287
Total liabilities and stockholders’ equity	$38,822	$43,309

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.